CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Infusion of ADV specific T cellsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02851576
NCT02851576Phase 2Completed
CompareCT.gov

Generation of Clinical Grade Adenovirus Specific T Cells for Adoptive Immunotherapy After Allogeneic Stem Cell Transplantation : Clinical Trial

Central Hospital, Nancy, France·interventional·Posted Aug 1, 2016·Updated Sep 15, 2016

In Brief

A Phase 2 clinical trial evaluating Infusion of ADV specific T cells for Adenovirus Infection. Completed, enrolled 14 participants across 1 site.

Detailed Summary

Fourteen patients will be included for infusion of adenovirus-specific T-cells generated by a clinical grade IFN-γ based immunomagnetic isolation from a leukapheresis from their original donor or a haploidentical donor, in case of Umbilical cord blood transplantation, in the event of refractory ADV infection or disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenovirus Infection
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 1, 2016
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.9 years ago

Interventions

Infusion of ADV specific T cellsother

Cell engineering